

TEIJIN PHARMA

CORPORATE
PROFILE

TEIJIN PHARMA LIMITED

Kasumigaseki Common Gate West Tower, 2-1,
Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-8585, Japan
<https://www.teijin-pharma.com/>

Product names and service names denoted with © or TM are registered trademarks or trademarks of the Teijin Pharma Limited in Japan and/or other countries in this brochure. Product names and service names used are registered trademarks or trademarks of the Teijin Pharma Limited. Other product names and service names may be protected as their trademarks and/or trade names.

©2023 Teijin Pharma Limited All Rights Reserved



Improving Quality of Life through Solutions Spanning All Stages of the Care Cycle

Teijin Pharma walks alongside every one of our patients. Within our core priority fields of bone, joint, rehabilitation, neurology, respiratory, cardiovascular and metabolic, we are responding to social change and taking steps to realize healthcare for the society of the future. Our goal is a society where people can live the lifestyle of their choice, regardless of their age. Our corporate philosophy, enhancing the quality of life, is our starting point for everything. By providing total healthcare solutions, we are evolving into a company that will support future society.



The Teijin Group has been part of the United Nations Global Compact since March 2011 and is working constantly on the Sustainable Development Goals for a more sustainable future. Teijin Pharma is particularly focussed on targeting Good Health and Well-being.

SUSTAINABLE DEVELOPMENT GOALS



In 2025, Japan's baby boomer generation will begin to turn 75. We predict this milestone will trigger rapid change in the medical treatment and nursing care of the elderly. As one of the world's few super-aged societies, Japan is where we, Teijin Pharma, are concentrating our efforts to develop a unique, new perspective on total healthcare solutions. We believe in supporting all stages of the care cycle, from disease prevention and healthy living, to treatment, rehabilitation, nursing care and lifestyle assistance, evolving to address the issues faced by patients, families and communities who are in need of more support.

Right now, our focus is on reinforcing Teijin Pharma's globally active drug development platform. As well as maintaining a network of administrative and sales locations established in communities across Japan, we are advancing new platforms including customer centers, home visit nursing stations and our *VitalLink*® patient information sharing system. While we are attuned to the issues faced by society at large, we endeavor to provide flexible and sensitive care that is optimized to patients as individuals, going beyond existing pharmaceutical, home healthcare and ICT frameworks. Further, we are prioritizing startup co-creation and diversity, particularly in the fields of rare and intractable diseases, to evolve conventional approaches. Every member of Teijin Pharma is an evolutionary leader, and our passion for breaking new ground is at the heart of every move we make.

Masaki Taneda
President, Teijin Pharma Limited



Multifaceted Solutions from the Teijin Group

Teijin's healthcare business was born from our advanced polymer research and development in the 1970s. R&D is part of our DNA. By integrating our well-established medical and pharmaceutical R&D capabilities with a wide range of technologies sourced from the Teijin Group's materials and IT business domains, we are adding depth to our unique, total-healthcare solutions. From promoting healthy lifestyles to supporting local health networks that span whole communities, we are building a range of products and services that contribute to all stages of healthcare.

Total Healthcare Solutions

Our healthcare approach isn't about imitating others. The Teijin Group has strengths and resources that are unique in a healthcare provider, allowing us to pioneer unique healthcare solutions. Through continuous development, we have evolved the treatment of bone and joint, respiratory, and cardiovascular and metabolic diseases. Naturally, we plan to continue this evolution, but we are also expanding our perspective. We are currently making steps into the fields of rehabilitation and neurology. Healthcare is not just treatment, but disease prevention, healthy living, chronic care, rehabilitation and nursing care. We have already begun establishing Teijin Group products in functional food and patient information sharing, and will continue formulating solutions that encompass all stages of healthcare.

Teijin Pharma puts patients at the center of everything. Close collaboration between our sales, home care and medical staff enables us to support patients' health as a team, together with medical professionals and care givers. Our specialized expertise allows us to accelerate the integration of pharmaceutical research with medical technology to create innovative healthcare solutions. As society evolves, the way healthcare is administered will change. By focusing on convalescent and chronic stage care, as well as acute stages, we are emphasizing community and its vital importance to healthcare. Within the Teijin Group we are fostering projects around regenerative medical products as part of our efforts to provide healthcare that supports the society of the future.




Community-based Integrated Care Requires the Right Balance of Technology and Humanity

Technology is bringing patients closer to medical professionals

As long-term healthcare evolves, community-based integrated care is becoming a vital element. Patients want stable access to services, including medical, residential, living assistance and nursing care, without being removed from their community and their preferred surroundings. To make this a reality, patient information needs to be organized and distributed in the best and most efficient way, enhancing collaboration among family physicians, visiting nurses, pharmacists, care workers and any other relevant parties. To enable medical professionals to watch over patients around the clock, our patient information sharing system, *VitalLink*®, is designed to work as part of a community. Relevant care workers, doctors and nurses are all able to continuously monitor patient data, such as body temperature or pulse, via *VitalLink*® on their PC or mobile device. It features timeline-style communication notebooks, enabling medical professionals to share care information easily between themselves and interact. With this system, changes to each patient's condition are noted at the earliest phase possible, making it easier to provide optimal care for patients as individuals.

Team Organization Supports Better Quality of Life for Our Patients

At Teijin Pharma, we don't just develop and manufacture products, we provide human resources. The best way to support both patients at home and medical professionals is to provide a knowledgeable and coordinated team behind every solution. We count home care professionals, nurses, laboratory technicians, occupational therapists and physical therapists as members of our team, as well as many others. Our sales staff are backed up by ample hands-on experience in both pharmaceutical and home healthcare. Thanks to this team organization, we can support both patients and medical professionals totally. Teijin Pharma has more than 100 locations across Japan. We are present in communities and capable of tailoring our services to provide the best solutions for each community. Patients are important parts of their communities, and so are we.



Core Priority Fields

Bone and Joint



Expertise Equal to Our 40 Years' Experience

In the 1980s, osteoporosis was not yet widely known as a disease. Nevertheless, we recognized the importance of taking measures against osteoporosis early and began by developing diagnostic procedures. Soon, we grew the field into pharmaceuticals, developing active vitamin D₃ drug, *Onealfa*®, formulated to increase bone mass, and arranging in-licensing for *Bonalon*®, a drug for treating osteoporosis by inhibiting loss of bone mass. We have since diversified into other treatments within the field of bone and joint, adding options such as *LOQQA*® tape, a transdermal anti-inflammatory analgesic patch formulation for osteoarthritis, and *SAFHS*®, a sonic accelerated fracture healing system.

Bonalon® is a trademark of Merck Sharp & Dohme Corp.
LOQQA® is a trademark of Taisho Pharmaceutical Co., Ltd.



Using the Strong Foundation of the Teijin Group

From drug development and medical equipment to implantable devices, the Teijin Group is realizing advanced, comprehensive solutions by synergizing healthcare expertise with materials technology. Teijin first established a joint prosthesis and spinal systems business in 2015, and followed up with the formation of a business handling bioresorbable bone fixation devices in 2017. Our solutions are expanding beyond bone and joint diseases and into the field of orthopedic surgery, and we plan to continue challenging that expansion.



Artificial joints

Core Priority Fields

Rehabilitation and Neurology



Recognizing the Importance of Mobility to Quality of Life

Motor skills and mobility are essential aspects to good quality of life. While developing treatments for bone and joint diseases, we saw the necessity for development in the field of rehabilitation and neurology. We took our first steps into the field with *WalkAide*®, an electrical stimulation device, and *ReoGo*®-J, a robotic device for rehabilitating the upper limbs. With devices like these, we are advancing the potential for recovery from impairments caused by damage to the central nervous system through stroke or other injuries or trauma.

ReoGo® is a trademark of Motorika Medical Ltd.




From First Symptoms to Rehabilitation

Preventing problems before they can occur is the drive behind our research into cerebrovascular diseases. Our new allogeneic regenerative medical product composed of dental pulp stem cells, intended to treat patients suffering acute cerebral infarction, is currently in clinical trials. On top of this ongoing work, we have signed an exclusive license and co-development agreement with Merz Pharma GmbH & Co. KGaA for a novel type A botulinum neurotoxin, covering all expected indications for ethical pharmaceutical use in Japan. The neurotoxin has great potential to improve quality of life for patients suffering spasticity.

Uncovering New Approaches to Depression

As awareness and knowledge about mental health increases, it is necessary to grow the range of treatments available. We launched the *NeuroStar*® Transcranial Magnetic Stimulation device under Japanese national health insurance coverage in 2019, in-licensing it from a medical device manufacturer in the United States. Drug-based antidepressant treatments are not effective for all patients and we are responding to this growing need for alternatives.



Core Priority Fields Respiratory



Pioneering Home Oxygen Therapy

Teijin manufactured Japan's first membrane-type oxygen concentrator in 1982. Before this breakthrough, patients suffering from chronic respiratory diseases, such as chronic obstructive pulmonary disease or sequela of tuberculosis, had to stay in hospital to receive treatment. Through our work with membrane-type oxygen concentrators, we helped open a new avenue of treatment called Home Oxygen Therapy, or HOT, which allows patients to receive treatment at home. We have continued efforts to grow HOT in Japan, acquiring approval for coverage under national insurance and building up a rental system to make HOT more accessible to patients.

24-hour Support for Patients

The core aim of our home healthcare services is to prioritize the comfort and safety of patients. We have multiple layers of patient contact built in to our solutions and an established service system tailored to provide the best solutions for each community, including home visit nursing stations, customer centers with 24-hour, 365-day service and a monitoring system that operates via telephone landlines. Our disaster mapping assistant partner (D-MAP), an emergency response support IT system, also helps us to support patients during emergency situations.



A Top-level Share in the Japan Market*

Since launching therapeutic oxygen concentrators for HOT, we have significantly expanded our home healthcare operations. Our current lineup includes a series of non-invasive positive pressure ventilation (NPPV) devices for patients suffering from chronic respiratory diseases and continuous positive airway pressure (CPAP) devices to treat sleep apnea syndrome (SAS). Our devices are small, quiet and practical, making them popular with both patients and medical professionals. *Hi-Sanso*®, our therapeutic oxygen concentrator for HOT, and *SLEEPMATE*®, our continuous positive airway pressure device for CPAP therapy, hold the top shares for their respective markets in Japan*. * Estimated from external reports and Teijin Pharma's rental volume.

Core Priority Fields Cardiovascular and Metabolic



Developed In-house with Worldwide Potential

Hyperuricemia, the excess of uric acid in the blood, has gained attention in recent years as a factor in lifestyle-related diseases, being linked to serious conditions such as gout or renal impairment. Teijin Pharma developed febuxostat in-house as a treatment for hyperuricemia and gout, and since initial development the drug has been recognized for its innovative approach and originality, receiving awards such as the Pharmaceutical Society of Japan Award for Drug Research and Development. Since its launch, febuxostat has grown to be distributed globally, with availability reaching 117 markets including Europe, North America and Asia as of March 2020.



Striving to Meet the Needs that Matter

We believe in providing choice and meeting the needs of the people who really matter – patients. Teijin Pharma in-licensed *Somatuline*®, a subcutaneous injection treatment for acromegaly and pituitary gigantism created by French pharmaceutical company, Ipsen Pharma to Japan, aiming to offer more varied treatment options for patients. In 2017, we successfully achieved additional approval from the Japanese regulatory authorities to distribute *Somatuline*® as a treatment for gastro-entero-pancreatic neuroendocrine tumors, a rare type of cancer.

*Somatuline® is a trademark of Ipsen Pharma



History

Tackling the ever-changing barriers around improving quality of life is complex. Every new challenge requires a new approach. Whether it's diseases with no known cure, diseases that lack awareness in society, or conditions for which treatment places a burden on patients, we focus on finding solutions through ceaseless evolution and ambition. That's our DNA.

Pioneering New Avenues of Treatment

The birth of home oxygen therapy (HOT) opened the door for home healthcare in Japan. Teijin built a rental system for HOT, ensuring that both patients and devices are supported 24/7, 365 days a year. At first, only seven fulltime members manned the system, able to rush to a patients' home should any problem occur. Their nickname became The Seven Samurai. These days, that philosophy of support still endures.

Passionate About New Paths of Treatment

In the 1980s, treatment options for hyperuricemia and gout were limited. Nevertheless, upon seeing figures on just how many patients suffered from these disorders, a researcher at Teijin Pharma started a project to create a new drug. Despite being granted only a two-year timeline, the project team was boosted by voluntary help from colleagues and ultimately led to the successful synthesis of febuxostat, a treatment for preventing excessive levels of uric acid.

Challenging the Field of Digital Healthcare

After initiating the HOT monitoring system and tackling data management for CPAP therapy, Teijin continued working on implementing ICT in healthcare, this time targeting information sharing between medical professionals, something that is essential for community-based, integrated care. Total healthcare requires links between every stage of care, something Teijin is evolving rapidly to provide.

2015

Launch of *VitalLink*® patient information sharing system, and opening of the Technology Integrated Pharmaceuticals Center

2019

Launch of *NeuroStar*® Transcranial Magnetic Stimulation device

2016

Launch of *ReoGo*®-J, a robot for rehabilitating paralyzed upper limbs

2013

Launch of *Somatuline*® subcutaneous injection treatment for acromegaly and pituitary giantism, and *WalkAide*® neuromuscular electrical stimulation device for walking support

2011

Launch of febuxostat, a treatment for hyperuricemia and gout

1974

The Teijin Institute for Bio-Medical Research established

1972

Pharmaceutical research begins

1971

Research commences on oxygen enrichment membranes

Utilizing High Polymer Chemistry

Research on membranes has been part of Teijin's broader research since the early 1950s. Initially directed towards potential uses in seawater filtration, when Teijin researchers discovered a film that could be used to separate the substances in gasses, the potential for medical applications came to light, including the first membrane-type oxygen concentrator for Japan.

1968

Studies begin at the Future Development Division of Teijin Limited

Starting from Zero

50 years after Teijin's formation as Japan's first commercial rayon producer, the company was busy expanding into other synthetic fibers, such as nylon and polyester. To help boost the globalization and diversification of business, the Future Development Division was formed and "Pharmaceutical" was added to a list of potential projects.

1986

Launch of *Hi-Sanso*® absorption-type oxygen concentrator

1985

HOT receives coverage under national health insurance

1981

Launch of *Onealfa*® active vitamin D₃ drug



1978

Iwakuni Pharmaceutical Factory established

1982

Home oxygen therapy (HOT) business created. Launch of membrane-type oxygen concentrator *Mild Sanso*®, the first such device to be manufactured in Japan



2000

Sleep apnea syndrome (SAS) treatment business created through the in-license of *SLEEPMATE*®, a continuous positive airway pressure device for CPAP therapy



1998

Launch of *SAFHS*® sonic accelerated fracture healing system



2003

Teijin Pharma Limited established

2001

Launch of *Bonalon*®, a drug for treating osteoporosis



Corporate Data

Company Name Teijin Pharma Limited
Established April 15, 2002
Capital 10,000 million Yen
Main Business Sales, Marketing, Manufacturing and R&D of Pharmaceuticals and Medical Devices

https://www.teijin-pharma.com/



Head Office

Kasumigaseki Common Gate West Tower, 2-1,
Kasumigaseki 3-chome, Chiyoda-ku,
Tokyo 100-8585, Japan
TEL : +81-3-3506-4077

Medicinal Chemistry Research Laboratories,
Pharmaceutical Discovery Research Laboratories,
Bio-Medical Engineering Laboratories

3-2, Asahigaoka 4-chome, Hino,
Tokyo 191-8512, Japan
TEL: +81-42-581-4321



Iwakuni Pharmaceutical Factory / Iwakuni Medical Factory

2-1, Hinodemachi, Iwakuni, Yamaguchi 740-8511, Japan
TEL : +81-827-24-6530 (Pharmaceutical Factory)
TEL : +81-827-24-6523 (Medical Factory)



Home Healthcare Technical
Service Center

1357, Minami Jo, Anpachi-cho, Anpachi-gun,
Gifu 503-0123, Japan
TEL: +81-584-64-5151

Overseas
Offices



Teijin America, Inc.

600 Lexington Avenue, 27th Floor,
New York 10022, USA
TEL: +1-212-308-8744



Yuyu Teijin Medicare Inc. (Republic of Korea)

Jongha building, 4th floor 27, Dongho-ro 15-gil,
Jung-gu, Seoul 04598, Korea
TEL: +82-2-2254-0285



London Office for Healthcare Business Group (UK)

3rd floor, 111 Buckingham Palace Road,
London SW1W 0SR, UK
TEL: +44-20-7340-8670



Esteve Teijin Healthcare S.L. (Spain)

Avda. Diagonal, 579, 8a planta, 08014
Barcelona, Spain
TEL: +34-93-887-5710

Alliance
Partners

Europe

Abiogen	GlaxoSmithKline Biologicals	Menarini
Almirall Hermal	Ipsen	Merz
Boehringer Ingelheim	Isdin	Sanofi
Covis	Leadiant	Sanofi Pasteur

Asia

Astellas Pharma	Hind Wing	PT Dipa Pharmed
Berli Jucker	Ilsung Pharmaceuticals	SK Chemicals
Chanh Duc	Pharmacon	Somedico
Dong Wha	Profex Inc.	Suzuken(SHENZHEN)Pharmaceutical

Middle East

Algorithm
Martin Dow Pharmaceuticals
Minapharm
Neopharm

Americas

Bioventus	Nox Medical
Innovative Neurotronics	Philips Respironics
Merck & Co.	ResMed
Mylan EPD	Takeda Pharmaceuticals U.S.A.
Neuronetics	